$ACHV Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.80 down -116.22% YoY
• Achieve Life Sciences anticipates potential FDA approval for cytisinicline in the first half of 2027, which will be followed by a U.S. commercial launch of the treatment for nicotine dependence.